CD19 and acute lymphoblastic leukemia: The anti-CD3/CD19 BiTE molecule blinatumomab, a fusion protein of two single-chain antibody fragments, was approved by the FDA in 2014 for treatment of ALL, and clinical response in patients with r/r NHL has been observed16–19.